Citation

Romundstad S, Holmen J, Kvenild K, Hallan H, Ellekjaer H. Am. J. Kidney Dis. 2003; 42(3): 466-473.

Affiliation

HUNT Research Center, Department of Public Health and General Practice, Norwegian University of Science and Technology, Verdal, Norway. solfrid.romundstad@medisin.ntnu.no

Copyright

(Copyright © 2003, National Kidney Foundation, Publisher Elsevier Publishing)

DOI

unavailable

PMID

12955674

Abstract

BACKGROUND: To date, there are few large follow-up studies of apparently healthy subjects with microalbuminuria (MA). The aim of this study is to examine the association between MA and all-cause mortality in nondiabetic nonhypertensive individuals. METHODS: We conducted a 4.4-year mortality follow-up of 2,089 men and women (> or =20 years) without diabetes and treated hypertension, randomly selected from the population-based Nord-Trøndelag Health Study (1995 to 1997; n = 65,258). Main outcome measures were adjusted relative risk (RR) for all-cause mortality according to increasing albuminuria, defined at different albumin-creatinine ratio (ACR) levels and in 1/2 or 3 urine samples. The main analysis was performed after exclusion of those with cardiovascular disease. RESULTS: There was a positive association between all-cause mortality and MA. The lowest ACR level associated with increased RR for mortality was the 60th percentile (> or =6.7 microg/mg [0.76 mg/mmol]; RR, 2.4; 95% confidence interval, 1.1 to 5.2), applying 3 urine samples with an ACR greater than the cutoff level. We found a positive association between mortality and increasing numbers of urine samples with an ACR greater than different cutoff levels, in which 3 urine samples were superior. Results persisted after adjusting for several confounders and excluding individuals with untreated hypertension (systolic blood pressure > or = 140 mm Hg/diastolic blood pressure > or = 90 mm Hg) and those who died during the first year of follow-up. CONCLUSION: Although this study confirms the association of all-cause mortality and ACR level in apparently healthy individuals, intervention trials are necessary before clinical cutoff levels of ACR are established and before screening programs are recommended.

Language: en